Cardiovascular health

What ApoB measures, and why it is missing from most reports

In short. ApoB counts the particles that carry cholesterol into the artery wall; LDL only weighs the cholesterol inside them. When the two disagree, risk follows ApoB, which is why it is worth measuring when LDL looks normal.

Two men of forty-five sit down with identical cholesterol reports. LDL 116 mg/dL on both. One has an ApoB of 74 mg/dL. The other, 128.

Same printout, same reassurance, and close to twice as many plaque-forming particles circulating in the second man. Neither of them had ApoB measured, because it is not on the panel.

What ApoB counts

Every particle capable of lodging in an artery wall carries exactly one apolipoprotein B molecule. One particle, one ApoB. That includes LDL, VLDL, IDL and lipoprotein(a), so a single ApoB value is a count of every atherogenic particle in the sample.

Three lipoprotein particles of different sizes, each encircled by one ApoB molecule A large, a medium and a small particle. Each is encircled by a single pale band representing one apolipoprotein B molecule, showing that particle size varies while the count of ApoB per particle does not. LARGE MEDIUM SMALL 1 ApoB per particle
Each particle carries exactly one ApoB molecule, whatever its size. Count the molecules and you have counted the particles.

LDL cholesterol is not a count. It measures how much cholesterol is being carried inside those particles. One number counts the vehicles; the other weighs the cargo.

The distinction is not academic. An artery is injured by particles entering the wall and getting trapped there, not by the quantity of cholesterol they happened to be carrying when they arrived.

Why two identical LDL results can mean different things

Particles are not uniform. The same total cholesterol can be carried by a smaller number of large particles or a larger number of small, dense ones.

Two blood samples with the same LDL cholesterol but different particle counts Left: six large particles. Right: fourteen small particles. Both carry the same amount of cholesterol, but the right sample has roughly twice the ApoB count. LOWER PARTICLE COUNT HIGHER PARTICLE COUNT LDL 116 mg/dLApoB 74 mg/dL LDL 116 mg/dLApoB 128 mg/dL
Schematic. Both samples carry the same cholesterol. The one on the right carries it in roughly twice as many particles, and it is the particle count that tracks risk.

When particles are small and dense, each one carries less cholesterol. LDL can therefore read as unremarkable while the number of particles is high. That situation has a name in the literature: discordance.

Who tends to be discordant

Discordance is not evenly distributed. It clusters in people with insulin resistance, triglycerides of 150 mg/dL or more, type 2 diabetes, and weight carried around the middle.

That matters locally, because the same cluster is common in South Asian populations and appears at body weights that look unremarkable on a Western chart. A WHO expert consultation set a BMI of 23, not 25, as the point to act in Asian populations, with lower waist limits to match. Someone can sit inside every printed range, look well, and still be carrying a particle count nobody has counted.

What is a good ApoB level

There is no single good ApoB. The target moves with overall cardiovascular risk, as it does for LDL.

European guidance (ESC/EAS) sets a target below 100 mg/dL for people at moderate risk, below 80 mg/dL at high risk and below 65 mg/dL at very high risk, and treats ApoB as a Class I measurement where diabetes, obesity, triglycerides of 150 mg/dL or more, or an LDL already driven low by treatment, are present. Those four situations are precisely the ones in which LDL is least trustworthy on its own.

What ApoB does not do

It does not separate out lipoprotein(a). Lp(a) carries an ApoB molecule and is counted in the total, but it is genetically set, it barely moves with diet or statins, and it needs its own test. Once in a lifetime is enough.

Nor is the argument fully settled. Whether treating to an ApoB target rather than an LDL target changes outcomes is still being worked out, and anyone telling you otherwise is ahead of the evidence. What is not in dispute is narrower and still useful: ApoB predicts cardiovascular events at least as well as LDL, and better than LDL when the two disagree.

Fasting and timing for an ApoB test

It is the same blood draw as a lipid profile, and fasting is not required, which is a practical advantage over a calculated LDL. It is not part of a standard panel in Sri Lanka, so it has to be requested by name.

For most people one measurement answers the question, because it either agrees with the LDL or it does not. If it disagrees, that changes what the rest of the report means.

Frequently asked questions

Is ApoB the same as LDL cholesterol?

No. LDL measures cholesterol carried inside particles. ApoB counts the particles, because each one carries exactly one apolipoprotein B molecule.

Do I need to fast before an ApoB test?

No. A recent meal does not meaningfully change it.

What is a good ApoB level?

It depends on your overall risk. European guidance uses below 100 mg/dL at moderate risk, below 80 mg/dL at high risk and below 65 mg/dL at very high risk.

My LDL is normal. Do I still need it?

A normal LDL is the situation where ApoB adds the most, because it is where the two most often part company.


If a report has already come back clear, the useful question is not whether anything was flagged. It is which particles were counted, and the honest answer for most panels in this country is none of them. Half of Sri Lankan adults have never had their cholesterol measured at all, and ApoB sits outside the standard panel even for those who have. ApoB is part of the Premium programme.

Sources

  1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020;41(1):111-188
  2. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2025;46(42):4359-4378
  3. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet, 2004;363(9403):157-163
  4. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF, 2006